Clinical trials
Localized Prostate Carcinoma clinical trials
Below are recruiting localized prostate carcinoma clinical trials, each written for real people, not researchers. We’re tracking 131 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Birmingham, AlabamaAges 18 years+ - NCT06946771Recruiting
MRI and prostate lesions: understanding diagnosis and prognosis
This trial uses MRI scans to study prostate lesions and see how they relate to diagnosis, pathology, and long-term outcomes. It may help patients with concerns about prostate health get more detailed imaging.
Wuhan, HubeiAges 18 years+ - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
Fayetteville, ArkansasAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT06052683Recruiting
Comparing radiation side effects for low-risk prostate cancer
This trial compares two types of radiation therapy (SBRT and LDR brachytherapy) for men with low-risk or favorable intermediate-risk prostate cancer. The goal is to see which treatment causes fewer side effects.
Québec, QuebecAges 18 years+ - NCT06861452RecruitingPhase 1/Phase 2
Testing a new drug after chemo for advanced pancreatic cancer
This study tests an investigational drug (RR001) given after chemotherapy for people with locally advanced pancreatic cancer that hasn't spread. It aims to see if the new treatment is safe and may help shrink tumors that can be reached with a needle injection.
Modena, ItalyAges 18 years+ - NCT06273345Recruiting
Treating the primary tumor for prostate cancer that has spread a little
This trial studies whether treating the main prostate tumor with local therapy (like surgery or radiation) along with hormone therapy is beneficial for men whose cancer has spread to only a few spots in the body (low-volume metastases). It focuses on men who have not had any prior treatment for their prostate cancer.
Brixen, BolzanoAges 18 years+ - NCT07699705Recruiting
Proton Beam Therapy for Localized Prostate Cancer
This study tests a very short course (ultrahypofractionated) of proton beam radiation for localized prostate cancer. It aims to see if it's safe and effective with fewer treatment visits.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT05344235Recruiting
Study of very short radiation schedules for prostate cancer
This observational study looks at how well men with localized prostate cancer do when treated with an unusually short radiation approach. It may help doctors understand which patients benefit most by tracking outcomes and imaging over time.
Leuven, Vlaams BrabantAges Any age - NCT06353906RecruitingPhase 2
Chemo plus immunotherapy for advanced penile cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
LeuvenAges 18 years+ - NCT06470217RecruitingPhase 2
Study of tirilizumab plus chemo for advanced oral cancer
This trial tests a combination of immunotherapy (tirilizumab) and two chemotherapy drugs (albumin-bound paclitaxel and cisplatin) for people with advanced but removable oral cancer. The goal is to see if this treatment shrinks the tumor before surgery and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT07218666RecruitingPhase 2
Zanzalintinib for aggressive prostate cancer
This trial tests a new drug, zanzalintinib, in men with a fast-growing type of prostate cancer that has spread and stopped responding to standard hormone therapies. It aims to see if the drug can help shrink tumors or slow the disease.
Milwaukee, WisconsinAges 18 years+ - NCT01961713Recruiting
Blood test study during prostate surgery for localized prostate cancer
This trial studies prostate cancer cells in the blood (“circulating tumor cells”) while you undergo planned prostate surgery. It may help doctors better understand prostate cancer and how it behaves early, which could guide future treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06893783RecruitingPhase 2
Tarlatamab for advanced extrapulmonary neuroendocrine carcinoma
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
SeoulAges 19 years+ - NCT06211335RecruitingPhase 1
Losartan, pembrolizumab and radiation for advanced head & neck cancer
This trial tests a combination of three treatments—a blood pressure drug (losartan), an immunotherapy (pembrolizumab), and targeted radiation—for people with head and neck cancer that has come back, spread to a few spots, or is not responding to other treatments. The goal is to see if this mix can shrink tumors and help patients who have few options left.
Sacramento, CaliforniaAges 18 years+ - NCT06448026RecruitingPhase 2
Cemiplimab and cetuximab before surgery for mouth or throat cancer
This trial tests whether combining two targeted drugs (cemiplimab and cetuximab) before surgery can help people with recurrent mouth or throat cancer that has come back after initial treatment. It aims to see if this approach makes surgery more effective.
Houston, TexasAges 18 years+ - NCT05376553Enrolling by invitationPhase 1
Test cemiplimab plus chemo before treatment for head and neck cancer
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
New York, New YorkAges 18 years+ - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT07006727RecruitingPhase 1
Targeted radiation therapy for DLL3-positive advanced cancers
This study tests a new targeted radiation therapy (called [225Ac]Ac-ETN029) for people with advanced cancers that have a protein called DLL3 on their cells. The treatment is designed to deliver radiation directly to cancer cells, and the goal is to see if it is safe and effective.
Iowa City, IowaAges 18–100 - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT06085664RecruitingPhase 1/Phase 2
Immunotherapy before prostate cancer surgery
This trial tests a new immunotherapy drug (REGN5678) given before surgery to men with high-risk prostate cancer that hasn't spread. The goal is to see if the drug can shrink or control the cancer before the prostate is removed.
Houston, TexasAges 18 years+ - NCT04678362RecruitingPhase 2
Maintenance treatment with talazoparib plus immunotherapy for bladder cancer
This trial tests whether continuing two medicines after your initial platinum chemotherapy can help keep your urothelial (bladder/urine tract) cancer from coming back or worsening. It is for people whose cancer shrank or stayed stable after chemotherapy and who cannot be cured with surgery or radiation.
AngersAges 18 years+
Hear when a new Localized Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for localized prostate carcinoma?
- Yes. Clin2 currently lists 131 recruiting localized prostate carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a localized prostate carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a localized prostate carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.